David Ricks, Eli Lilly CEO (Jeenah Moon/Bloomberg via Getty Images)
July 2, 2024 02:02 PM EDTUpdated 03:20 PM
Pharma
FDA+

Up­dat­ed: Eli Lil­ly wins long-await­ed ap­proval for Alzheimer’s drug

Ryan Cross

Senior Science Correspondent

Af­ter decades of try­ing to de­vel­op a treat­ment for Alzheimer’s dis­ease, Eli Lil­ly has fi­nal­ly won FDA ap­proval for its drug do­nanemab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times